Detection of vancomycin heteroresistant Staphylococcus haemolyticus and vancomycin intermediate resistant Staphylococcus epidermidis by means of vancomycin screening agar [9]

Pathology

Volumn 39, Issue 3, 2007, Pages 375-377

  Chiew, Yoke Fong ^a   Charles, Musuka ^a   Johnstone, Maree C ^a   Thompson, Kim M ^a   Parnell, Kyle D ^a   Penno, Erin C ^a  

^a DUNEDIN HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; LINEZOLID; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGRAFT; ANAMNESIS; ANTIBIOTIC RESISTANCE; BACTERIAL GROWTH; BLOOD CULTURE; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; CULTURE MEDIUM; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEVER; HUMAN; LETTER; MALE; NEUTROPENIA; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS HAEMOLYTICUS; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION;

EID: 34250197871     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020701330441     Document Type: Article

References (12)

1. Ortega M, Rovira M, Almela M, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol 2005; 84: 40-6.
2. Falcone M, Micozzi A, Pompeo MF, et al. Methicillin-resistant staphylococcal bacteremia in patients with hematologic malignancies: clinical and microbiological retrospective comparative analysis of S. haemolyticus, S. epidermidis and S. aureus. J Chemother 2004; 16: 540-8.
3. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
4. Von Eiff C, Arciola CR, Montanaro L, et al. Emerging Staphylococcus species as new pathogens in implant infections. Int J Artif Organs 2006; 29: 360-7.
5. Raponi G, Ghezzi MC, Gherardi G, et al. Antimicrobial susceptibility, biochemical and genetic profiles of Staphylococcus haemolyticus strains isolated from the bloodstream of patients hospitalized in critical care units. J Chemother 2005; 17: 264-9.
6. Walsh TR, Bolstrom A, Qwarnstrom A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 2439-44.
7. Clinical and Laboratory Standards Institute (CLSI), Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. Volume 26, Number 3, , Wayne, PA: CLSI, Cat. no. M100-S16.
8. Srinivasan A, Dick JD, Perl TM. Vancomycin resistance in staphylococci. Clin Microbiol Rev 2002; 15: 430-8.
9. Costa SF, Barone AA, Miceli MH, et al. Colonization and molecular epidemiology of coagulase-negative staphylococcal bacteremia in cancer patients: a pilot study. Am J Infect Control 2006; 34: 36-40.
10. Center KJ, Reboli AC, Hubler R, et al. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of Staphylococcus warneri. J Clin Microbiol 2003; 41: 4660-5.
11. Van der Zwet WC, Debets-Ossenkopp YJ, Reinders E, et al. Nosocomial spread of a Staphylococcus capitis strain with heteroresistance to vancomycin in a neonatal intensive care unit. J Clin Microbiol 2002; 40: 2520-5.
12. Vanderbilt University Medical Center Guidelines for VRSA (Vancomycin Resistant Staphylococcus Aureus); VRSE (Vancomycin Resistant Staphylococcus Epidermidis); VISA (Vancomycin Intermediate Staphylococcus Aureus); VISE (Vancomycin Intermediate Staphylococcus Epidermidis), IC 10-10.08. http://vumcpolicies.mc.vanderbilt.edu/E-Manual/Hpolicy.nsf/AllDocs/ EEB3513A4CD9C3E186256B5F00790092, accessed March 2007.